HOME >> BIOLOGY >> NEWS
Enzymes Targeted As Key To Understanding Drug Interactions

You go to one doctor for your back problem. You see another for high blood pressure. Perhaps you consult a third for a nagging sinus infection. As part of your treatment, each writes a prescription or two. The result can be an array of pill bottles on your bathroom counter or breakfast table, perhaps augmenting your usual arsenal of over-the-counter supplements and pain and cold remedies.

How is the patient -- or the health care professional -- to know when the potential exists for a serious, even life-threatening, interaction between medications? Or when one drug may render another ineffective? News stories have highlighted the problem of pharmacists who failed to question prescriptions for dangerous drug combinations, and pharmacists complain of computer programs that fail to give them adequate warning of possible interactions.

A notorious example of a potentially deadly drug duo was Seldane, a popular antihistamine, and erithromycin, a common antibiotic, which when taken together could produce sometimes fatal heart problems. The U.S. Food and Drug Administration (FDA) has recommended that Seldane be withdrawn from the market.

Prevention of drug interactions, say researchers at the University of Washington School of Pharmacy, lies in learning how the human body processes each drug.

The school has recently established a formal Program in Drug Interactions, tapping the expertise of 22 faculty members believed to be the largest group of experts in the world on drug interactions.

The UW investigators are seeking systematic knowledge of how various enzymes -- biochemical catalysts produced by the body -- metabolize drugs. Their research is producing an understanding of the potential for adverse effects among thousands of drug combinations.

"Pharmacists have had to remember hundreds of pairs of drugs that interact," said the program's director, Dr. Rene Levy, professor and chair of pharmaceutics. "But there was a shift in our knowedge
'"/>

Contact: Laurie McHale
lmchale@u.washington.edu
206-543-3620
University of Washington
28-May-1997


Page: 1 2

Related biology news :

1. Constructing "Designer" Plant Enzymes
2. Engineering New Enzymes
3. Spinach Enzymes Neutralize Explosives
4. Worm Wizardry: Worlds Most Heat-Tolerant Creature Suggests Enzymes For Drugs OrIndustry, UD Prof Says
5. Targeted therapy knocks out pediatric brain cancer in mice
6. Targeted therapy for lung cancer patients shows promise in extending lives
7. Targeted immunotherapy eradicates cancer in mice
8. Targeted radiation to liver tumors spares tissue, improves quality of life
9. Targeted Genetics presents data on arthritis gene therapy
10. Targeted genetics presents promising data from cystic fibrosis clinical trial
11. Targeted Genetics presents clinical data on E1A cancer gene therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... , ... Global Stem Cells Group CEO Benito Novas announced that ... GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in ... hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM Professor ...
(Date:4/26/2016)... CA (PRWEB) , ... April 26, 2016 , ... ... healthcare, today announced that Ardy Arianpour has joined the company as Chief Business ... of experience bringing innovative genomic technologies to market, was most recently Chief Commercial ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research ... financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. ... biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, Darryl ...
(Date:4/26/2016)... -- genae, a Contract Research Organization (CRO) ... the appointment of Prof. Dr. Jörn Balzer to the ... include all clinical, safety and risk management related to ... honored with the acceptance of Prof. Balzer to join ... genae. "Prof. Balzer,s impressive and extensive background make him ...
Breaking Biology Technology:
Cached News: